KalVista Pharmaceuticals (KALV) Other Non-Current Assets (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Other Non-Current Assets of $2.4 million in Q3 2025, up 53.55% quarter-over-quarter from $1.5 million in Q2 2025, and up 292.89% year-over-year from $605000.0 in Q3 2024.
KalVista Pharmaceuticals' Other Non-Current Assets history runs 12 years deep, the most recent figure standing at $2.4 million for Q3 2025.
- In Q3 2025, Other Non-Current Assets rose 292.89% year-over-year to $2.4 million; the TTM figure through Jul 2025 stood at $2.4 million (up 292.89% YoY), while the FY2025 annual figure was $1.5 million, up 173.02% from the prior year.
- Other Non-Current Assets came in at $2.4 million for Q3 2025 at KalVista Pharmaceuticals, up from $1.5 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.4 million in Q3 2025 to a low of $106000.0 in Q2 2023.
- A 5-year average of $518736.8 and a median of $200000.0 in 2021 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets plunged 51.38% in 2023 and soared 470.75% in 2024, its largest moves.
- KalVista Pharmaceuticals' Other Non-Current Assets stood at $193000.0 in 2021, then increased by 2.07% to $197000.0 in 2022, then jumped by 71.07% to $337000.0 in 2023, then jumped by 309.2% to $1.4 million in 2024, then soared by 72.37% to $2.4 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.4 million, $1.5 million, and $1.4 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 2.38 Mn |
| Apr 30, 2025 | 1.55 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Oct 31, 2024 | 662,000.00 |
| Jul 31, 2024 | 605,000.00 |
| Apr 30, 2024 | 567,000.00 |
| Jan 31, 2024 | 397,000.00 |
| Oct 31, 2023 | 337,000.00 |
| Jul 31, 2023 | 106,000.00 |
| Apr 30, 2023 | 106,000.00 |
| Jan 31, 2023 | 197,000.00 |
| Oct 31, 2022 | 197,000.00 |
| Jul 31, 2022 | 218,000.00 |
| Apr 30, 2022 | 193,000.00 |
| Jan 31, 2022 | 193,000.00 |
| Oct 31, 2021 | 193,000.00 |
| Jul 31, 2021 | 200,000.00 |
| Apr 30, 2021 | 200,000.00 |
| Jan 31, 2021 | 181,000.00 |
| Oct 31, 2020 | 178,000.00 |
| Jul 31, 2020 | 178,000.00 |
| Apr 30, 2020 | 178,000.00 |
| Jan 31, 2020 | 173,000.00 |
| Oct 31, 2019 | 173,000.00 |
| Jul 31, 2019 | 173,000.00 |
| Apr 30, 2019 | 173,000.00 |
| Jan 31, 2019 | 173,000.00 |
| Oct 31, 2018 | 173,000.00 |
| Jul 31, 2018 | 173,000.00 |
| Apr 30, 2018 | 173,000.00 |
| Jan 31, 2018 | 173,000.00 |
| Apr 30, 2017 | 50,000.00 |
| Mar 31, 2016 | 50,000.00 |
| Dec 31, 2015 | 991,000.00 |
| Sep 30, 2015 | 218,000.00 |
| Jun 30, 2015 | 50,000.00 |
| Mar 31, 2015 | 50,000.00 |
| Dec 31, 2014 | 50,000.00 |